AbbVie Strengthens Evidence For Rinvoq In Crohn's
Executive Summary
Over 10 datasets presented at Digestive Disease Week strengthen the case that clinicians should view AbbVie’s selective JAK inhibitor Rinvoq as a powerful addition to their clinical toolbox for moderate-to-severe Crohn’s disease patients. However, safety concerns will keep it as second-line treatment in the US after its likely label expansion this month.
You may also be interested in...
From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs
Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.
Fostering a Culture of Innovation, From Evolutionary To Revolutionary
Innovation is a key to long-term success for biopharma companies, but building the right climate to foster creative problem-solving is challenging. Questioning assumptions and constraining the target of innovation can propel a company forward.
Radical Honesty Is Part Of The Secret To Apellis's Success
On the heels of Apellis's wildly successful launch for the geographic atrophy drug Syfovre, the company's co-founder and CEO spoke with In Vivo about what it takes to go from a start-up to a commercial-stage company and about the importance of honesty in leadership.